UT-15C is an oral sustained release formulation of treprostinil, the active ingredient in United Therapeutics’ Remodulin, which is currently marketed for subcutaneous and intravenous treatment of pulmonary arterial
ISIS 113715, a second-generation antisense drug, reduces the expression of protein tyrosine phosphatase-1B (PTP-1B). PTP-1B is a mediator of insulin resistance, one of two main defects in patients
The JEWEL program, (JEWEL I and JEWEL II) funded by Pfizer, was comprised of two studies that were conducted in the UK and Canada (JEWEL I) and 11
The data, presented by Novartis at the meeting of the European Society of Hypertension in Madrid, Spain, demonstrated robust efficacy and a good safety profile for the drug
Status asthmaticus is a long-lasting and severe asthma episode in which asthma symptoms are not responsive to initial bronchodilator or corticosteroid therapy. Status asthmaticus is an emergency situation
The collaboration, also supported by the Biologics Delivery Systems Group of Cordis Corporation, will focus on dosing, delivery and targeting of the ViaCell stem cells using Cordis’ NOGA
Wellbutrin XL is the first and only medication approved to prevent seasonal major depressive episodes. Although antidepressant medications have been used to treat acute seasonal major depressive episodes
The deal involves four Discovery Partners International (DPI) sites in the US, Germany, and Switzerland which will be merged into BioFocus, the drug discovery services division of Galapagos.
The research involved leptin, the hormone that turns off hunger but fails to cross into the brain to regulate appetite in obese people. According to Dr Susan Farr,
The priority review designation means that the FDA will try to complete its review of the drug within six months, rather than the usual nine. The designation was
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.